ArticleAnnals of surgical oncology2025
Intraoperative Radiation Therapy (IORT) for Breast Cancer: The Final Analysis of a Prospective Cohort of 1828 Cases.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ASO Author Reflections: Intraoperative Radiation Therapy (IORT): Near Dead in the USA.Annals of surgical oncology · 2025Article
- ASO Author Reflections: Advancing Esophagojejunostomy: Reflecting on the Evolution of Nasogastric Tube Techniques.Annals of surgical oncology · 2025Article
- Multidisciplinary strategies to reduce radiotherapy-induced cardiotoxicity in breast cancer: surgical and technological innovations.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntraoperative radiation therapy (IORT) delivers the full course of radiation therapy during the initial surgical excision. In the early 2000s, IORT was a promising method of breast cancer treatment de-escalation, offering many advantages. This technique should have succeeded in the USA, but several factors hindered its widespread adoption. We report the results of our 15-year IORT registry trial and our reasons for halting the trial. PATIENTS AND
methodsPatients with early-stage breast cancer were entered into an institutional review board (IRB) approved registry. They were analyzed by intention to treat and by various subgroups, including those who received local treatment to the area of the primary tumor only versus those who received additional whole breast treatment.
resultsA total of 1785 patients with 1828 early-stage breast cancers entered the registry. With a median follow-up of 85 months, the local recurrence rate (LRR) at 5-years for the entire cohort was 4.44%. Among 1527 who received local treatment only, the LRR at 5-years was 5.09% compared with 1.13% for 301 patients who received additional whole breast treatment (p = 0.001). For patients aged ≥ 65 with luminal A tumors ≤ 20mm, the 5-year LRR dropped to 2.32%.
conclusionsIORT is extremely convenient for the patient and offers many advantages when compared with other methods of partial or whole breast treatment. Overall, the LRR for IORT is 4-5 times higher than many competing forms of whole or accelerated partial breast irradiation but still relatively low. A more select choice of patients for IORT can lower the LRR. Following the decision by ASTRO in 2024 not to recommend IORT, and considering a number of other factors, our group made the decision to discontinue our IORT program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.